Introduction
Progressive cardiac conduction disease (PCCD) is one of the major causes of pacemaker implantation in developed countries. 1 It is a slowly evolving lifespan disease that progressively affects cardiac conduction, leading ultimately to pacemaker implantation to prevent the risk of complete atrioventricular block and Stokes-Adams syncope. The disease was initially attributed to an age-related fibrotic degeneration of atrio-ventricular and/or ventricular conduction system. 2 There is no available pharmacological treatment to prevent the progression of the disease. There is thus a need to understand perfectly the pathophysiological mechanisms of the disease and to identify molecular targets involved in its early phases.
SCN5A, which encodes the cardiac sodium channel Na V 1.5 , was the first gene associated to PCCD. 3 Two other genes have also been related to the disease: SCN1B, which encodes one of the regulatory b-subunits of Na V 1.5, 4 and TRPM4, which encodes a Ca 2þ -permeable non-selective cation channel. 5, 6 Mutations of SCN5A gene lead to a loss of function and/or expression of Na V 1.5. 7 Since the haploinsufficiency is present early during development, the disease was thought to result from combined Na þ channel dysfunction and aging-related unknown processes. 7 To understand the pathophysiology of PCCD, we studied a Scn5a heterozygous knockout (Scn5a þ/-) mouse model 8 and showed that this model exhibits an age-related deterioration in conduction and ventricular fibrosis and remodelling of connexin 43 (Cx43) expression in old mice. [9] [10] [11] Scn5a þ/-mice thus appeared as a unique model to elucidate PCCD pathophysiological mechanisms and identify molecular targets for developing preventive treatments. Our previous studies have shown that Scn5a þ/-mice exhibited fibrotic remodelling around coronary vessels as early as 14-16 weeks of age and increased myocardial interstitial fibrosis, together with focal fibrosis, over 50 weeks. [9] [10] [11] In the older Scn5a þ/-mice (83 ± 3 weeks), the extent of fibrosis seemed to be linked to the severity of primary conduction defects: mice exhibiting the more severe QRS complex prolongation when young had more myocardial, mainly focal, fibrosis when old. Moreover, 50% of old Scn5a þ/-mice with a severe phenotype exhibited spontaneous ventricular arrhythmias. 9 However, the kinetics of occurrence of myocardial interstitial and focal fibrosis were not clearly determined. This represents crucial information to identify the molecular mechanisms linking Na V 1.5 decreased expression to fibrosis. In this context, the objectives of the present study were (i) to determine more precisely the kinetics of myocardial fibrotic remodelling in this model of PCCD, (ii) to identify the signalling pathway(s) at the origin of fibrosis development, and (iii) if possible, based on the signalling pathway(s) identified, to prevent myocardial pathological fibrotic remodelling. For this purpose, we combined electrocardiographic, echocardiocardiographic, biochemical, and immunohistological studies on wild-type (WT) and Scn5a þ/-mice at the ages of 10, 20, 30, 45 , and 60 weeks. Our study shows that myocardial fibrosis does not increase progressively with ageing but is triggered by the activation of TGF-b pathway only after the age of 45 weeks. Our results also suggest that this process involves a decrease of Na V 1.5 expression, rather than a decrease in Na þ current per se. To finish, transforming growth factor b (TGF-b) receptor inhibition prevents age-dependent development of ventricular fibrosis.
Methods

Ethics statement
Animal experiments were performed in the animal facility of Nantes University Health Research Institute (Unité 
Electrocardiography
All mice (129/Sv genetic background) were genotyped by polymerase chain reaction as previously described. 10 Mice were anaesthetized for ECG recording with etomidate (25 mg/kg i.p.). Body temperature was maintained at 37 C with a heating pad (Harvard Apparatus, USA 
Assessment of cardiac function by echocardiography
Echocardiography was performed on mice using a Vivid-7 Dimension ultrasonography (GE Healthcare, UK) with a 14-MHz transducer. See online data supplement for method description.
Cardiac fibrosis remodelling investigations
Age-related cardiac fibrosis remodelling in WT and Scn5a þ/-mice was investigated at the ages of 10, 30, 45, and 60 weeks. Cardiac fibrosis was also investigated at the age of 60 weeks in WT mice treated chronically with flecainide or placebo and in Scn5a þ/-mice treated with GW788388 or placebo. See Supplementary material online, data supplement for method description.
Western-blot analysis and zymography
Protein samples were prepared from the left ventricular free walls. Each western blot was made in duplicate and quantification was performed with Image Lab TM Software (Bio-rad, USA) and normalized to GAPDH and total protein amount. See Supplementary material online, data supplement for methods description.
In vivo treatments with flecainide and GW788388
For flecainide, 129/Sv WT mice (male and female) were chronically treated orally (drinking water) with flecainide at 50 mg/kg/day from the age of 6 weeks to the age of 20, 30, and 60 weeks. Flecainide was dissolved in water. For GW788388, 45-week-old Scn5a þ/-mice were treated orally chronically until the age of 60 weeks at a dose of 5 mg/kg/day. GW788388 was dissolved in dimethyl sulfoxide (DMSO). The maximum concentration of DMSO in drinking water was 0.2% in both GW788388-and placebo-treated groups.
Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM 
. Results
As in our previous study, 9 two groups of Scn5a þ/-mice could be distinguished at the age of 9-11 weeks based on QRS complex duration (calculated as in Figure 1A of reference 10 ): one group with a mild QRS prolongation (QRS < _ 18 ms; 'mild') and one group with a severe phenotype (QRS> 18 ms; 'severe'; see Supplementary material online, Figure  S1 ). Phenotype severity in Scn5a þ/-mice was not influenced by gender (male/female) as previously shown. 9 As shown in Figure 1A (see also Leoni et al. 9 ), RR interval, P wave duration, and PR interval of these two groups of mice did not differ among Scn5a þ/-mice but were significantly prolonged vs. WT mice.
3. Figure S2 ). In contrast, Cx43 expression in WT mice decreased significantly between the ages of 45 and 60 weeks (see Supplementary material online, Figure S2 ). Development of fibrosis at the age of 60 weeks was associated with a moderate decrease in contractile function as assessed with echocardiography in Scn5a þ/-mice with severe QRS prolongation ( Figure 2) . In young animals (16 weeks), echocardiographic parameters of Scn5a þ/-mice did not differ from those of WT animals (data not shown).
Fibrotic remodelling is triggered by the activation of TGF-b pathway
In order to decipher the pathophysiological pathway(s) involved in ventricular fibrosis remodelling, we investigated the activation of matrix metalloproteinases. In WT mice, no change in the gelatinolytic activity of the 72 kDa matrix metalloproteinase 2 (MMP2) was detected between 30 and 60 weeks of age (see Supplementary material online, Figure S3 ). In Scn5a þ/-mice of both phenotypes, its activity was high at 30 weeks and decreased to reach WT level in older mice ( Figure 3 ). MMP9 activity was not modified (data not shown). Besides, expression of tissue inhibitors of metalloproteinases (TIMP) did not vary along time and in any group (see Supplementary material online, Figure S4 ). Then, we compared the expression of Cx43 and Nav1.5 between WT and Scn5a þ/-mice at different ages ( Figure 4 and see Supplementary material online, Figure S5 ). The difference in Na V 1.5 expression between WT and Scn5a þ/-remained constant during aging whereas Cx43 expression varied. Up to 30 weeks, young Scn5a þ/-mice showed a higher expression of Cx43 than WT mice but this expression decreased to reach WT levels at 45 weeks and later ( Figure 4 and see Supplementary material online, Figure S5 ). of age on RR interval, P wave duration, PR interval, and QRS complex duration of WT (white symbols; n = 32) and Scn5a þ/-mice with mild (grey symbols; n = 35) and severe (black symbols; n = 17) phenotype. Each mouse used for this figure was submitted to ECG recording at all ages mentioned in abscissa. Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak test for multiple comparisons. *P < 0.05, **P < 0.01, *** P < 0.001. RR interval duration significantly decreased with age (P < 0.001) similarly in all groups of mice. In contrast PR interval duration significantly increased with age (P < 0.001) similarly in all groups of mice. The effect of age on QRS interval was larger in Scn5a Figure S5 ). All together, these results suggest that interstitial fibrotic remodelling depends on the activation of TGF-b pathway rather than on CTGF increased expression.
Chronic inhibition of Na V 1.5 does not induce TGF-b overexpression and fibrotic remodelling
Scn5a þ/-mice are characterized by both a decreased expression of Na V 1.5 at the membrane and, consequently, a decreased Na þ current. In Scn5a þ/-severe, n = 6. Statistical analysis was performed using one-way ANOVA followed by Dunnett post hoc test for multiple comparisons. *P < 0.05. cation relative to the GAPDH bands and normalized to WT ratio (n = 6 per group). Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001. order to investigate whether decreasing the Na þ current without alteration of Na V 1.5 expression could activate the same pathway and induce fibrosis, we inhibited Na V 1.5 activity by treating WT mice with flecainide chronically from the age of 6 weeks to the age of 60 weeks. As shown in Figure 5 , flecainide markedly prolonged QRS duration to values close to those observed in Scn5a þ/-mice with a mild phenotype ( Figure 5A) .
TGF-b inhibition prevents fibrosis in
Similarly, no ventricular dilation was observed in 60-week-old mice treated with flecainide ( Figure 5B) . But in contrast to Scn5a þ/-mice, even those with mild QRS prolongation, there was no fibrosis in mice treated with flecainide as compared to placebo group ( Figure 5C ). This result is correlated with similar expression of TGF-b and CTGF in placebo-and flecainide-treated mice ( Figure 5D ). There was also no difference in Na V 1.5 and Cx43 expression. Altogether, these results suggest that a decrease in Na þ current per se is not enough to induce TGF-b pathway activation and fibrotic remodelling.
TGF-b receptor inhibition prevents agedependent development of ventricular fibrosis
In order to confirm TGF-b pathway involvement in the development of fibrosis, we treated Scn5a þ/-mice chronically from the age of 45 weeks did not show any sign of fibrotic remodelling at the age of 60 weeks ( Figure 6A and B) . Moreover, the expression of Smad2/3 phosphorylated form and CTGF was normalized in GW788388-treated mice ( Figure 6C and D) . GW788388-treated mice also showed a higher Cx43 expression than placebo-treated mice. Altogether, these experiments support our hypothesis that fibrotic remodelling in Scn5a þ/-mice involves the activation of TGF-b pathway. Figure S6 ) and normalized to WT ratio (n = 5 per group). Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test for multiple comparisons. *P < 0.05, **P < 0.01. (E) Individual and average (red symbols) values of QRS complex duration of Scn5a þ/-mice recorded in lead I (top) and lead aVF (bottom) before and after treatment with placebo (n = 15) or GW788388 (n = 9). Statistical analysis was performed using two-way ANOVA for repeated measures. For lead I, there was a significant difference between the placebo and the GW788388 groups (P = 0.03) but the effect of age did not reach significance (P = 0.10). There was no interaction between treatments and age (P = 0.82). For lead aVF, there was a significant difference between the placebo and the GW788388 groups (P = 0.04) and a statistical effect of age (P = 0.03), but no interaction between treatments and age (P = 0.71). The effects of GW788388 on age-related QRS prolongation were also investigated ( Figure 6E) . Unfortunately, mean QRS duration in lead I before treatment differed between placebo and GW 788338 groups (P < 0.05; Student t-test). QRS duration was also measured in lead aVF, as this lead was recently proposed as being more relevant than lead I for estimating ventricular conduction time 12 ; although the difference in QRS duration in lead aVF between the two groups was reduced, it remained significant (P < 0.05), thus complicating the interpretation of the data. Nevertheless, there was no significant interaction between the effects of the treatments and the effects of aging. The values of QRS prolongation during treatment did not differ between placebo and GW788388 groups, for both lead I (þ1.1 ± 0.8 ms under GW 788338 vs. þ1.5 ± 1.1 ms under placebo) and aVF (þ1.1 ± 0.7 ms under GW 788338 vs. þ1.5 ± 0.8 ms under placebo; 9 and 15 mice respectively; Mann-Whitney rank sum test). Thus, preventing fibrosis development did not prevent QRS prolongation between the ages of 45 and 60 weeks.
TGF-b inhibition prevents fibrosis in
Discussion
This study shows (i) that myocardial interstitial and focal fibrosis in Scn5a þ/-mice increases only after the age of 45 weeks, (ii) that this fibrotic remodelling involves the activation of TGF-b signalling pathway, (iii) that this process occurs simultaneously with physiological decrease in Cx43 expression with ageing, (iv) that the decrease in Na þ current per se is not sufficient to induce TGF-b activation and fibrosis, and (v) that pharmacological inhibition of TGF-b type I and type II receptors prevents fibrosis in Scn5a þ/-mice.
The current study adds to previous studies on Scn5a þ/-mice. Scn5a
mice were shown to present conduction defects [8] [9] [10] and sinus node dysfunction. 13 One interesting feature of this model is the progressiveness of ventricular conduction defects with ageing, 9-11 reflecting in some aspects the clinical phenotype of patients with inherited SCN5A-related PCCD. 7 This age-dependent deterioration of ventricular conduction was proposed to be linked to the occurrence of fibrosis in ventricular myocardium. Increased perivascular fibrosis could be detected in Scn5a þ/-mice as early as 14-16 weeks of age, 10 but myocardial interstitial and focal fibrosis could be detected only in old (50-80 weeks) mice. 9, 10 This was the first demonstration that cardiac fibrosis could be the final outcome of an ion-channel defect. 10, 11 In the present study, one first objective was to determine more precisely the time course of fibrosis occurrence with a focus on interstitial and focal myocardial fibrosis, which was proposed to be an important factor for reducing global ventricular conduction. 14, 15 We show that the increase of myocardial fibrosis is not linear but appears only after the age of 45 weeks. Interestingly, fibrosis development does not seem to alter much ventricular conduction in Scn5a þ/-mice, at least between 45 and 60 weeks of age, since QRS prolongation during this period of time is similar in Scn5a þ/-and WT mice. This is confirmed by the absence of effect of GW788388 treatment on QRS duration despite a prevention of fibrosis development. The impact of fibrosis might be different in older mice. Indeed, in a previous study, we have shown that after 80 weeks of age, the Scn5a þ/-mice with the largest fibrotic remodelling were more prone to developing spontaneous ventricular tachycardia. 9 In older Scn5a þ/-mice, there was more fibrosis in animals with severe conduction defect than in those with mild conduction defects. In the present study, at the age of 60 weeks, the moderate difference between the two groups does not reach significance, suggesting that although fibrotic remodelling starts at the same age in the two phenotypes, it seems exacerbated with age in Scn5a þ/-mice with the severe phenotype.
Myocardial fibrotic remodelling in
Scn5a þ/À mice is triggered by TGF-b
Our second objective was to determine the pathophysiological pathway(s) involved in interstitial fibrosis development. For this purpose, we investigated the expression of proteins previously shown to be involved in fibrotic remodelling in other models. Our study shows that Scn5a þ/-mice are characterized by two phases of ventricular remodelling. During the first phase, i.e. before the age of 45 weeks, there is an increase in CTGF expression, a pro-fibrotic protein that has been shown to play key roles in fibrogenesis. 16 TGF-b is a regulator of CTGF expression, but an up-regulation of CTGF is not necessarily associated to an up-regulation of TGF-b/smad2/3 pathway. Indeed, Adam and collaborators have shown that mice constitutively overexpressing active Rac1 at the cardiac level have an up-regulation of CTGF and Cx43 protein expression without any significant alteration of TGFb1 expression. 17 At this age, Scn5a þ/-mice are also characterized by a higher activity of MMP2. Cardiac fibrosis can result from an increase in collagen expression and maturation or from a decrease in the breakdown of collagen fibres, which is regulated by metalloproteinases, including MMP2. 18, 19 Interestingly, CTGF has been shown as a potent promoter of MMP2 expression and activity. 20 MMP2 increased activity, in the absence of TIMP upregulation, might limit fibrosis development. This could lead to an increased collagen turnover and limit fibrosis development. CTGF, on its own, is considered as a weak promoter of fibrosis. Recent studies using mice overexpressing or knockout for CTGF have shown that CTGF in not the main actor for cardiac fibrosis development. 21, 22 However, cooperative interactions between CTGF and TGF-b signalling are required 23, 24 and may contribute to fibrosis development when TGF-b pathway is activated. The second phase is characterized by an increase in TGF-b expression and the activation of its canonical phospho-Smad2/3 pathway at the age of 45 weeks prior fibrosis. At this age, the high expression of CTGF is further increased, whereas MMP2 activity is normalized. Altogether, these results suggest that TGF-b signalling is the major fibrotic factor involved in Scn5a þ/-mice. This hypothesis is supported by our observation that the inhibition of TGF-b pathway after TGF-b receptor block, fully prevents fibrotic remodelling. The time course of events leading to fibrosis development is summarized in Figure 7 .
The mechanism linking Na V 1.5 haploinsufficiency and activation of TGF-b pathway is unclear. Aging-related fibrosis associated with Na V 1.5 deficiency in the sinoatrial node of Scn5a þ/-mice was also shown to involve TGF-b signalling. 25 Our study with flecainide chronic treatment suggests that a decrease in cardiac Na þ current is not sufficient to induce the activation of TGF-b pathway and fibrosis development as observed in Scn5a þ/-mice. To the best of our knowledge, putative effects of chronic cardiac sodium channel blockade on fibrosis and/or TGF-b remodelling had never been investigated. In vitro Na V 1.5-E3 antibody has been shown to increase TGF-b production by both cardiomyocytes and fibroblasts. Interestingly, this effect was not only associated with a 50% decrease in Na þ current, but also with a 20% decrease in Na V 1.5 expression. 25 Therefore, one explanation to connect Na V 1.5 haploinsufficiency and increased TGF-b signalling could be through disorganization of the Na V 1.5 protein complex. Indeed, Na V 1.5 multiprotein complex may exert a regulatory role in cellular biological processes in addition to its electrophysiological function. 26 Although the detailed mechanistic link between disruption of Na V 1.5 complex and TGF-b secretion needs further investigation, our findings have important implication for possible mechanisms underlying correlation between Na V 1.5 membrane expression and cardiac remodelling.
Fibrotic process in Scn5a
þ/À mice occurs simultaneously with Cx43 remodelling Our study shows that Cx43 expression is higher in young Scn5a þ/-mice than in WT mice prior to the activation of TGF-b pathway and fibrosis development. This suggests that Nav1.5 decrease is partly compensated by Cx43 higher expression in younger Scn5a þ/-mice. However, in older Scn5a þ/-mice (45 and 60 weeks old), this expression decreased to reach WT levels. Interestingly, this normalization occurs at the same time as TGF-b activation and fibrosis development. Since Cx43 expression naturally decreases during this period of time in WT mice (see Supplementary material online, Figure S2 ), the drop in Cx43 expression in Scn5a þ/-is big. Previous studies had shown that fibrosis is associated with a decrease in Cx43 expression. 11, 27 Recently, Fontes et al. 28 showed, in a mouse model of cardiac hypertrophy and fibrosis, that a reduction of Cx43 and Na V 1.5 expression preceded an up-regulation of TGF-b and CTGF expression and development of fibrosis. Interestingly, GW788388 treatment induced a moderate though significant increase in Cx43 expression in our study, as also observed in a rat model of myocardial infarction. 29 Further studies are needed to understand the relative role and relationship between these two major actors of cardiac conduction in cardiac fibrosis development.
TGF-b receptor inhibition: a new therapeutic perspective for fibrotic remodelling related to PCCD?
In order to demonstrate TGF-b implication in fibrotic process, we used GW788388, a specific inhibitor of both type I and type II TGF-b receptors. 30 GW788388 has been shown to reduce ventricular remodelling and systolic dysfunction in the rat model of myocardial infarction 29 and to prevent cardiac fibrosis in a mouse model of Chagas disease. 31 In our study, we observed that GW788388 prevented fibrotic development in Scn5a þ/-mice. This result not only confirms TGF-b pathway implication in fibrotic process in Scn5a þ/-mice but also paves the way to new therapeutic approaches for treating fibrotic remodelling related to cardiac conduction diseases. Our study suggests that preventing fibrosis does not prevent agerelated QRS prolongation in Scn5a þ/-mice, at least between 45 and 60 weeks of age. This weak relationship between fibrosis development and QRS duration is also suggested by the observation that QRS prolongation in Scn5a þ/-mice between 45 and 60 weeks was similar to that in WT mice ( Figure 1) . Similarly, Stein and coworkers also observed that preventing the development of fibrosis in senescent WT mice by treating them with eplerenone and/or losartan from the age of 52 weeks to the age of 88 weeks, did not modify QRS duration. 32 In their study, the only difference between non-treated and treated mice was that transversal conduction velocity in the right ventricle (not in the left) was significantly faster in treated mice. However, Stein and coworkers also observed that preventing fibrosis development did prevent the occurrence of pacinginduced arrhythmias. 33 In a previous study on Scn5a þ/-mice, 9 we have shown that fibrotic remodelling at the age of 80 weeks was larger than in the present study at 60 weeks and was associated with spontaneously occurring ventricular tachyarrhythmias in 50% of the Scn5a þ/-mice, suggesting that preventing fibrosis development could be beneficial in this context. On this basis, it would be interesting to investigate the effects of GW788388, or other compounds known to inhibit fibrosis development, on cardiac conduction, arrhythmia occurrence and contractilitysince 60 week-old Scn5a þ/-mice exhibit a moderate decrease in ejection fraction-on a longer period of time that in the present study.
Study limitations
In order to determine if the activation of TGF-b pathway was due to a decrease in Na V 1.5 expression or function, WT mice were treated chronically with flecainide. As mentioned earlier chronic inhibition of the Na þ current was not enough to induce an increase in TGF-b and fibrosis development. One could argue that the treatment with flecainide was started in 6-week-old mice whereas the loss in Na V 1.5 expression in Scn5a þ/-mice plays a key role as early as day 10.5 in the embryo. 8 However, abnormal prenatal and/or postnatal cardiac development does not seem to be involved in the activation of TGF-b pathway and fibrosis since those occur later in the adult mouse life. In the present study, we did not detect any contractile effect of flecainide, although it was previously reported to induce negative inotropic effects. However, those are modest in patients or animal models with normal cardiac function 32, 34, 35 and are more pronounced in diseased hearts, especially in the context of severe conduction disorders. 32, 36 In the mouse model, it was shown that flecainide treatment does not modify cardiac contractile function in control mice but unmasks discrete myocardial dysfunction in mice with myotonic dystrophy type 1 as assessed by tissue Doppler echocardiography. 37 Interestingly, standard echocardiography did not allow to detect any effect in those mice. This suggests that the absence
